A medical food in mild Alzheimer's disease

( these trials have started in Europe )

Please Help Support Alzheimer's Research Today! 
Your Alzheimer's donation will help billions live without it.
DONATE NOW

The hypothesis that combinations of certain nutrients could provide clinically relevant benefits to patients with AD formed the basis of the development of the medical food* Souvenaid, which is a multinutrient drink designed to improve synapse formation. Souvenaid contains the necessary precursor and supporting nutrients to act synergistically to enhance membrane formation and function in patients with AD. All components contained in this medical food have a history of safe use in other foods. This report presents the results of the first clinical trial evaluating the efficacy, tolerability, and safety of a medical food designed to restore synapses in brains of patients with mild AD. Group of scientists designed a proof-of-concept clinical trial to investigate whether supplementation with Souvenaid could affect cognitive functions in AD. This proof-of-concept study showed that supplementation with the multi-nutrient drink Souvenaid for 12 weeks is well-tolerated and results in an improvement in memory in patients with mild AD. Further clinical trials with this product in patients with AD are justified, with Souvenaid given both as add-on therapy in patients with mild to moderate AD receiving approved anti-AD medication, and in drug-naïve patients in order to confirm and extend the results of the current study. Future clinical trials aim to measure relevant biomarkers, in support of the hypothesis that Souvenaid can improve synapse formation. Read more: sciencedirect.com

TODAY'S PHOTO    

   

Functional foods 

Watching recent actions by scientific agencies, regulators and industry players themselves of late, one might be forgiven for thinking that the functional foods dream is falling a little short of the reality. Read more: nutraingredients.com

Беларусь ТВ

Posted YVN (AMYLOID @ PHOTO)